Skip to content

Effect of CBD-Hemp oil, a Sublingual Health Supplement on Sleep Quality in Male Shift Workers with Sleep Disorder

Effect of CBD-Hemp Oil, a Sublingual Health Supplement, on Sleep Quality and Sleep-Related Physiological Parameters in Male Shift Workers with Sleep Problems: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20260623007
Enrollment
60
Registered
2026-06-23
Start date
2026-06-22
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep problems related to shift work Shift work sleep disorder Sleep quality CBD-Hemp Oil Cannabidiol Sublingual supplement Shift work Sleep quality Sleep disorder PSQI Sleep tracker Heart rate variability Randomized controlled trial Placebo MCT oil

Interventions

Participants in the experimental arm will receive CBD Hemp Oil as a sublingual health supplement. The product contains cannabidiol from hemp in MCT oil. Participants will administer 5 drops equal to 0
Experimental Dietary Supplement,Placebo Comparator Dietary Supplement
CBD Hemp Oil,Placebo MCT Oil

Sponsors

Suan Sunandha Rajabhat University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Male participants aged 20 to 60 years. 2. Currently working in rotating shifts or night shifts for at least 3 months prior to enrollment. 3. Having shift work-related sleep disturbance, defined by poor sleep quality according to the study screening criteria, such as PSQI score > 5. 4. Generally healthy based on medical history and screening assessment. 5. Able to understand the study procedures and provide written informed consent. 6. Willing to comply with the study protocol, including use of the wearable device and completion of sleep questionnaires.

Exclusion criteria

Exclusion criteria: 1. History of severe psychiatric, neurological, cardiovascular, hepatic, renal, or respiratory disease. 2. Diagnosed sleep disorders not related to shift work, such as obstructive sleep apnea, narcolepsy, or restless legs syndrome. 3. Current use of sleeping pills, sedative drugs, antidepressants, antipsychotics, melatonin, cannabis products, or other products that may affect sleep within 2 weeks prior to enrollment. 4. Known allergy or hypersensitivity to CBD-Hemp oil, MCT oil, or any component of the study product. 5. History of alcohol or substance abuse. 6. Abnormal liver or renal function tests considered clinically significant by the investigator. 7. Participation in another clinical trial within 30 days prior to enrollment. 8. Inability or unwillingness to comply with the study procedures.

Design outcomes

Primary

MeasureTime frame
Sleep quality Baseline, week 1, week 4, and week 8 Pittsburgh Sleep Quality Index (PSQI)

Secondary

MeasureTime frame
Sleep efficiency (%) Baseline 7-night monitoring period and weekly 7-night averages throughout the 8-week intervention. Average sleep efficiency (%) measured by Xiaomi Smart Band 10 via Mi Fitness. Defined as total sleep time divided by time in bed x 100.

Countries

Thailand

Contacts

Public ContactWaisith Boontheppratan

Suan Sunandha Rajabhat University

s66584955004@ssru.ac.th0818696699

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026